Moderator: Alan S. Hilibrand, MD
83. Postoperative opioids and 1-year outcomes after spine surgery
Catherine Carlile, MD1; Jeffrey M. Hills, MD2; Clinton J. Devin, MD3; Kristin R. Archer, PhD, DPT3; Jacquelyn S. Pennings, PhD3
1Nashville, TN, US; 2Vanderbilt Orthopaedics, Nashville, TN, US; 3Vanderbilt University Medical Center, Nashville, TN, US
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
84. Incidence and predictors of long term opioid use following cervical spine fusion surgery
Sameh Abolfotouh, MD1; Casey A. Fogarty1; Julia Matera, BS2; Abigale M. Berry, BS3; Mostafa A. Abolfotouh, PhD4; Theodore J. Choma, MD5; Christina L. Goldstein, MD, FRCSC1
1Missouri Orthopedics Institute, Columbia, MO, US; 2Columbia, MO, US; 3University of Missouri School of Medicine, Columbia, MO, US; 4KAMC, Riyadh, Saudi Arabia; 5Missouri Spine Center, Columbia, MO, US
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
85. Unexpected post-operative clinical encounters with elective cervical spine surgery patients: can we predict them?
Jose H. Jimenez-Almonte, MD, MS1; Ifeanyi N. Nzegwu, MD2; Syed K. Mehdi, MD3; Boshen Liu, MD3; Jonathan D. Grabau, BS4; Zeeshan Akhtar, MA4; Cale Jacobs, PhD4; R. Carter Cassidy, MD5
1University of Kentucky, Kentucky Clinic, Lexington, KY, US; 2University of Kentucky Department of Orthopedic Surgery and Sports Medicine, Lexington, KY, US; 3University of Kentucky, Lexington, KY, US; 4Lexington, KY, US; 5UK Healthcare/Dept of Orthopaedics, Lexington, KY, US
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
86. Rate of revision surgery following multilevel posterior cervical fusion at the cervicothoracic junction
Bryan T. Head, MD1; Christopher D. Chaput, MD2; Mark D. Rahm, MD3; Robert S. Russell, MD4
1Baylor Scott and White Orthopaedics, Temple, TX, US; 2UT Health, San Antonio, TX, US; 3Baylor Scott and White Health, Temple, TX, US; 4Temple, TX, US
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
87. Effects of spinal decompression on the gait efficiency and balance of cervical spondylotic myelopathy patients: preliminary results
Lawal Labaran1; Varun Puvanesarajah, MD2; Hamid Hassanzadeh, MD3
1Richton Park, IL, US; 2Johns Hopkins Medicine, Baltimore, MD, US; 3University of Virginia, Department of Orthopedic Surgery, Charlottesville, VA, US
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
88. Asymptomatic ACDF non-unions underestimate the true prevalence of radiographic pseudoarthrosis
Charles H. Crawford III, MD; Leah Y. Carreon, MD, MSc; Steven D. Glassman, MD
Norton Leatherman Spine Center, Louisville, KY, US
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.>
89. 3D evaluation and classification of the anatomy variations of vertebral artery at the craniovertebral junction
Yiheng Yin, MD; Xinguang Yu, MD
Chinese PLA General Hospital, Beijing, CT, China
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
Discussion